1. Volume 156, Issue 6, Pages 1731-1741 (May 2019)
Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma 
Michael Teufel, Henrik Seidel, Karl Köchert, Gerold Meinhardt, Richard S. Finn, Josep M. Llovet, Jordi Bruix 
Gastroenterology 
Volume 156, Issue 6, Pages (May 2019)
DOI: /j.gastro
Copyright © 2019 AGA Institute Terms and Conditions

2. Figure 1 RESORCE patient subgroups for biomarker analyses.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2019 AGA Institute Terms and Conditions

3. Figure 2
Hierarchical clustering of baseline gene expression data for (A) all 46 samples (32 regorafenib, 14 placebo) and (B) 32 samples from regorafenib-treated patients. DC, dendritic cell; HBV, hepatitis B virus; HCV, hepatitis C virus; N, no; NK, natural killer; Th1, type 1 T helper cell; Treg, regulatory T cell; Y, yes.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2019 AGA Institute Terms and Conditions

4. Figure 3
Protein dichotomized subgroup analysis for OS regorafenib treatment benefit. Error bars denote 95% CIs of the treatment HR. Note, the HR reference level line was set to 1. HR <1 indicates regorafenib treatment benefit. Dichotomized protein expression was categorized into high (>median) vs low (≤median). Cox models were adjusted for Eastern Cooperative Oncology Group performance status, AFP level, macrovascular invasion presence, geographical region, and extrahepatic disease presence.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2019 AGA Institute Terms and Conditions